Prostate cancer trials in Poland

In Poland 39 Also abroad 1480

39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Bydgoszcz, Grudziądz, Kielce, Koszalin, Siedlce, Szczecin
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Cracow, Gdansk, Katowice, Skorzewo
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 3Taking people
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Where
Bialystok, Bydgoszcz, Koszalin, Warsaw
Age
18 years and over
People
1,203 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00
Phase 3Taking people
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Where
Cracow, Grudziądz, Koszalin, Lublin, Opole, Piotrkow Trybunalski, Torun, Warsaw, Wroclaw
Age
18 years and over
People
900 worldwide
Run by
Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Bydgoszcz, Cracow, Katowice, Poznan, Siedlce, Warsaw
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Krakow, Lódz, Szczecin
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 1/2Taking people
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Where
Koszalin, Piotrkow Trybunalski, Przemyśl
Age
18 years to 130 years
People
283 worldwide
Run by
AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00
No phaseTaking people
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Where
Many Locations
Age
18 years and over
People
1,600 worldwide
Run by
Bayer
See details and how to joinNCT07344779
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Gdansk, Krakow, Warsaw
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 2Taking people
177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
Where
Gliwice
Age
18 years and over
People
200
Run by
Maria Sklodowska-Curie National Research Institute of Oncology
See details and how to joinNCT06449781 · EU 2023-504912-13-00
Phase 3Taking people
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Where
Bialystok, Cracow, Gliwice, Kielce, Lodz, Lublin, Poznan, Siedlce, Skorzewo, Sosnowiec, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
736 worldwide
Run by
BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Bydgoszcz, Cracow, Koszalin, Warsaw
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Cracow, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Cracow, Gdynia, Gliwice, Koszalin, Piotrkow Trybunalski, Poznan, Rzeszow, Warsaw
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Cracow, Gdynia, Koszalin, Lublin, Poznan, Rzeszow, Szczecin, Wroclaw, Wrocław
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
Gdansk, Koszalin, Poznan, Warsaw
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
Poznan
Age
18 years and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Bydgoszcz, Gdansk, Otwock, Poznan, Wroclaw
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Cracow, Gliwice, Warsaw
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
No phaseTaking people
PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
Where
Zamość
Age
18 years and over
People
1,000
Run by
Affidea Nu-med Center of Oncological DIagnostics and Therapy
See details and how to joinNCT07691697
Phase 2Taking people
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Where
Gdansk, Gliwice, Myslowice, Otwock
Age
18 years and over
People
218 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00
Phase 1Taking people
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Where
Cracow, Gdansk, Lodz, Poznan, Warsaw
Age
18 years and over
People
180 worldwide
Run by
Duke Street Bio Ltd
See details and how to joinNCT06458712 · EU 2023-508805-26-00
Phase 1/2Taking people
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Where
Cracow, Gdansk, Warsaw
Age
18 years and over
People
52 worldwide
Run by
AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Gdansk, Poznan, Warsaw
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 3Not yet taking people in Poland
A clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate cancer
Where
Piotrkow Trybunalski
Age
18 years and over
People
63 worldwide
Run by
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
See details and how to joinNCT03520478 · EU 2024-515194-10-00